| Knowledge gaps . | Available evidence . | Feasibility of study . | Ongoing trials . |
|---|---|---|---|
| Role of combination of potassium and sodium channel blockers (amiodarone + propafenone/flecainid) in patients with ICD and frequent adequate interventions/arrhythmic storm | Observational | Moderate | None |
| Safety of Class IC in combination with beta-blockers in patients with ICD and frequent adequate interventions/arrhythmic storm | Observational | Feasible | None |
| Azimilide in patients with ICD and frequent adequate interventions/arrhythmic storm | RCT SHIELD, SHIELD-2 | Likely | None |
| Underpowered | |||
| Use of AAD during resuscitation for refractory VF/VT | Underpowered trials | Moderate | None |
| Role of ranolazine (inhibitor of late INa) in preveng non-sustained VT and SCD in patients post-ACS | MERLIN-TIMI 36, post hoc analysis | Moderate | RAID trial (NCT NCT01215253) |
| Targeted therapy with AAD for treatment of frequent ventricular ectopy | Observational | Likely | None |
| Targeted AAD therapy for cardiac channelopathies | Observational | Moderate | None |
| Role of late sodium current blockers (mexiletine, lidocaine) in preventing TdP by reducing drug-induced QTc prolongation | Healthy volunteers | Likely | None |
| Knowledge gaps . | Available evidence . | Feasibility of study . | Ongoing trials . |
|---|---|---|---|
| Role of combination of potassium and sodium channel blockers (amiodarone + propafenone/flecainid) in patients with ICD and frequent adequate interventions/arrhythmic storm | Observational | Moderate | None |
| Safety of Class IC in combination with beta-blockers in patients with ICD and frequent adequate interventions/arrhythmic storm | Observational | Feasible | None |
| Azimilide in patients with ICD and frequent adequate interventions/arrhythmic storm | RCT SHIELD, SHIELD-2 | Likely | None |
| Underpowered | |||
| Use of AAD during resuscitation for refractory VF/VT | Underpowered trials | Moderate | None |
| Role of ranolazine (inhibitor of late INa) in preveng non-sustained VT and SCD in patients post-ACS | MERLIN-TIMI 36, post hoc analysis | Moderate | RAID trial (NCT NCT01215253) |
| Targeted therapy with AAD for treatment of frequent ventricular ectopy | Observational | Likely | None |
| Targeted AAD therapy for cardiac channelopathies | Observational | Moderate | None |
| Role of late sodium current blockers (mexiletine, lidocaine) in preventing TdP by reducing drug-induced QTc prolongation | Healthy volunteers | Likely | None |
AAD, antiarrhythmic drug; ACS, acute coronary syndrome; ICD, implantable cardioverter-defibrillator; SCD, sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia.
| Knowledge gaps . | Available evidence . | Feasibility of study . | Ongoing trials . |
|---|---|---|---|
| Role of combination of potassium and sodium channel blockers (amiodarone + propafenone/flecainid) in patients with ICD and frequent adequate interventions/arrhythmic storm | Observational | Moderate | None |
| Safety of Class IC in combination with beta-blockers in patients with ICD and frequent adequate interventions/arrhythmic storm | Observational | Feasible | None |
| Azimilide in patients with ICD and frequent adequate interventions/arrhythmic storm | RCT SHIELD, SHIELD-2 | Likely | None |
| Underpowered | |||
| Use of AAD during resuscitation for refractory VF/VT | Underpowered trials | Moderate | None |
| Role of ranolazine (inhibitor of late INa) in preveng non-sustained VT and SCD in patients post-ACS | MERLIN-TIMI 36, post hoc analysis | Moderate | RAID trial (NCT NCT01215253) |
| Targeted therapy with AAD for treatment of frequent ventricular ectopy | Observational | Likely | None |
| Targeted AAD therapy for cardiac channelopathies | Observational | Moderate | None |
| Role of late sodium current blockers (mexiletine, lidocaine) in preventing TdP by reducing drug-induced QTc prolongation | Healthy volunteers | Likely | None |
| Knowledge gaps . | Available evidence . | Feasibility of study . | Ongoing trials . |
|---|---|---|---|
| Role of combination of potassium and sodium channel blockers (amiodarone + propafenone/flecainid) in patients with ICD and frequent adequate interventions/arrhythmic storm | Observational | Moderate | None |
| Safety of Class IC in combination with beta-blockers in patients with ICD and frequent adequate interventions/arrhythmic storm | Observational | Feasible | None |
| Azimilide in patients with ICD and frequent adequate interventions/arrhythmic storm | RCT SHIELD, SHIELD-2 | Likely | None |
| Underpowered | |||
| Use of AAD during resuscitation for refractory VF/VT | Underpowered trials | Moderate | None |
| Role of ranolazine (inhibitor of late INa) in preveng non-sustained VT and SCD in patients post-ACS | MERLIN-TIMI 36, post hoc analysis | Moderate | RAID trial (NCT NCT01215253) |
| Targeted therapy with AAD for treatment of frequent ventricular ectopy | Observational | Likely | None |
| Targeted AAD therapy for cardiac channelopathies | Observational | Moderate | None |
| Role of late sodium current blockers (mexiletine, lidocaine) in preventing TdP by reducing drug-induced QTc prolongation | Healthy volunteers | Likely | None |
AAD, antiarrhythmic drug; ACS, acute coronary syndrome; ICD, implantable cardioverter-defibrillator; SCD, sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
